TRADE NEWS: Agilent Technologies Introduces Two Innovative Products to Advance Clinical Cancer Research
26 Fevereiro 2015 - 1:00PM
Business Wire
HaloPlexHS Target Enrichment
System and ClearSeq Comprehensive Cancer Research Panel Improve
Speed and Accuracy of Variant Detection
Agilent Technologies Inc. (NYSE:A) today launched two new
products—the HaloPlexHS target enrichment system and ClearSeq
Comprehensive Cancer research panel—designed to improve the speed
and accuracy of clinical cancer research.
Both products will enable researchers to rapidly and accurately
identify disease-associated variants in tumor samples—information
that can be vital to research in cancer treatments.
The company is showcasing its new products at the annual
Advances in Genome Biology and Technology (AGBT) conference in
Marco Island, Florida, this week.
HaloPlexHS Target Enrichment System
HaloPlexHS is a high-sensitivity amplicon-based targeted
sequencing method based on Agilent’s innovative HaloPlex
technology. This new method enables clinical researchers to meet
one of their most daunting challenges: accurately identifying
low-frequency somatic variants in solid tumors and hematological
cancers.
One of the first commercially available high-sensitivity
target-enrichment technologies for next-generation sequencing,
HaloPlexHS incorporates more than 1 million unique molecular
barcodes for accurate detection of alleles at low frequencies. The
molecular barcodes are especially important for cancer researchers
who work with heterogeneous samples in which driver mutations can
be present in subclonal cell populations.
“We needed a highly sensitive, specific and rapid method for
detection of mutations below 1 percent for tumor burden
monitoring,” said Dr. Eric Duncavage, director of molecular
pathology training at Washington University in St. Louis, Missouri.
“HaloPlexHS proved to be the ideal product for this research
application. I expect HaloPlexHS to be the new clinical research
standard for accurate low-frequency variant identification.”
ClearSeq Comprehensive Cancer Panels
ClearSeq, an off-the-shelf cancer research panel developed in
collaboration with researchers at Washington University, provides
an accelerated solution for the analysis of many oncogenes and
tumor suppressors. This panel is the latest addition to Agilent’s
growing portfolio of ClearSeq cancer research panels and targets
151 key oncology genes containing disease-associated variants.
Designed with the clinical researcher in mind, the new panel
allows clinical researchers to rapidly profile multiple mutations
present in cancer samples.
“Cancer is a complex disease caused by genetic alterations in
multiple genes, many of which are present at very low frequency,”
said Jacob Thaysen, president of Agilent’s Diagnostics and Genomics
group. “These latest additions to Agilent’s portfolio of sequencing
solutions provide innovative methods to enable the identification
of important variants with greater accuracy than what is available
today. Together with industry-leading cancer diagnostic tools from
our Dako portfolio, Agilent offers a unique set of solutions that
provide a more comprehensive view of cancer, from discovery
research through diagnostics.”
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A), a global leader in life
sciences, diagnostics and applied chemical markets, is the premier
laboratory partner for a better world. Agilent works with customers
in more than 100 countries, providing instruments, software,
services and consumables for the entire laboratory workflow.
Agilent generated revenues of $4.0 billion in fiscal 2014. The
company employs about 12,000 people worldwide. Information about
Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and
executive news is available at www.agilent.com/go/news.
for Agilent Technologies Inc.Jennifer Mann, +1
303-357-2391jmann@webershandwick.com
American Oil & Gas Common Stock (NYSE:AEZ)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
American Oil & Gas Common Stock (NYSE:AEZ)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024